It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Molecular investigations are crucial for further developments in precision medicine. RNA sequencing, alone or in combination with further omic-analyses, resulted in new therapeutic strategies. In this context, biobanks represent infrastructures to store tissue samples and body fluids in combination with clinical data to promote research for new predictive and prognostic biomarkers as well as therapeutic candidate molecules. Until today, the optimal storage conditions are a matter of debate especially with view to the storage temperature. In this unique approach we compared parallel samples from the same tumour, one half stored at − 80 °C and one half in the vapor phase of liquid nitrogen, with almost identical pre-analytical conditions. We demonstrated that RNA isolated from breast cancer samples revealed significantly higher RINe-values after 10 years of storage in the vapor phase of liquid nitrogen compared to storage at − 80 °C. In contrast, no significant difference was found regarding the DIN-values after DNA isolation. Morphological changes of the nucleus and cytoplasm, especially in the samples stored at − 80 °C, gave insights to degenerative effects, most possibly due to the storage protocol and its respective peculiarities. In addition, our results indicate that exact point-to point documentation beginning at the sample preparation is mandatory.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Regensburg, Institute of Pathology and Central Biobank Regensburg, Regensburg, Germany (GRID:grid.7727.5) (ISNI:0000 0001 2190 5763)
2 University Medical Centre Regensburg, Department of Gynaecology and Obstetrics, Regensburg, Germany (GRID:grid.411941.8) (ISNI:0000 0000 9194 7179)
3 University Regensburg, Institute of Pathology and Central Biobank Regensburg, Regensburg, Germany (GRID:grid.7727.5) (ISNI:0000 0001 2190 5763); University Clinic and University Regensburg, Central Biobank Regensburg, Regensburg, Germany (GRID:grid.7727.5) (ISNI:0000 0001 2190 5763)
4 Patients’ Tumor Bank of Hope (PATH-Biobank) Foundation, Munchen, Germany (GRID:grid.7727.5)